Chong Kun Dang Pharmaceutical
Clinical trials sponsored by Chong Kun Dang Pharmaceutical, explained in plain language.
-
New combo therapy aims to control diabetes without side effects
Disease control Not yet recruitingThis study compares two different drug combinations for people with type 2 diabetes whose blood sugar is not well controlled with metformin and sitagliptin. About 200 adults will receive either empagliflozin or glimepiride added to their current treatment. The goal is to see whic…
Phase: PHASE4 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
New drug combo for BRCA ovarian cancer enters early testing
Disease control Not yet recruitingThis early-stage study tests two drugs, CKD-215 and D215, in 24 adults aged 19-75 with advanced BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer. The goal is to compare how the body processes each drug and check for side effects. Participants will receive both d…
Phase: PHASE1 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 08, 2026 13:07 UTC
-
New prostate drug enters early safety testing
Knowledge-focused Not yet recruitingThis early-stage trial tests a new drug called CKD-846 in 32 healthy men with benign prostate hypertrophy (enlarged prostate). The main goal is to see how the drug moves through the body and if it is safe. Participants must be men aged 19 to 55 with a healthy weight.
Phase: PHASE1 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Knowledge-focused
Last updated Jun 03, 2026 12:04 UTC